非何杰金氏淋巴瘤治疗市场 - 依类型（B 细胞 [瀰漫性大细胞、滤泡细胞、套细胞]、T 细胞 [週边、皮肤、间变性大细胞]、治疗类型（化疗、放射、标靶治疗））、性别 -全球预测（2024 - 2032）

Non-Hodgkin Lymphoma Therapeutics Market - By Type (B-cell [Diffuse Large, Follicular, Mantle Cell], T-cell [Peripheral, Cutaneous, Anaplastic Large Cell], Therapy Type (Chemotherapy, Radiation, Targeted Therapy)), Gender - Global Forecast (2024 - 2032)

出版日期: 2024年05月30日 | 出版商:

Global Market Insights Inc. | 英文 150 Pages | 商品交期: 2-3个工作天内

价格

简介目录

由于药物开发的进步和治疗选择的扩大，全球非何杰金氏淋巴瘤治疗市场在 2024 年和 2032 年期间复合年增长率将达到 7.4%。标靶治疗和联合治疗等药物创新提高了治疗各种淋巴瘤亚型的有效性。这些进步解决了未满足的医疗需求并提供了个人化的治疗方法。随着新疗法的开发和批准，它们为患者和医疗保健提供者提供了更多选择，有助于增加市场需求和更广泛的有效治疗选择。

例如，2023年4月，FDA批准了Polivy®（polatuzumab vedotin-piiq）合併Rituxan®（利妥昔单抗）等药物，标誌着20年来首个新的B细胞淋巴瘤治疗方法。此组合可降低 27% 的疾病进展风险。这种新疗法可显着降低疾病进展风险，增强 B 细胞淋巴瘤患者的治疗选择。 20年后推出这样一种新颖疗法，凸显了市场的创新和成长潜力。它可能会增加对新疗法开发的兴趣和投资，影响市场动态并扩大治疗选择。

非何杰金氏淋巴瘤治疗市场根据类型、治疗类型、性别和地区进行分类。

到 2032 年，由于人们对 T 细胞淋巴瘤复杂多样的亚型的认识不断增强，T 细胞淋巴瘤细分市场将显着增长。此细分市场的成长是由对标靶治疗的需求以及对 T 细胞淋巴瘤具体机制了解的进展所推动的。持续的研究和开发工作正在创造更有效和个人化的治疗方法，解决 T 细胞淋巴瘤带来的独特挑战并改善患者的治疗效果，从而推动市场扩张。

由于化疗作为主要治疗方法的既定作用，其在 2024 年至 2032 年间将大幅成长。化疗仍然是治疗非何杰金氏淋巴瘤的基石，有效地瞄准和破坏癌细胞。其广泛的可用药物和在疾病各个阶段已被证实的疗效有助于其占据市场主导地位。随着正在进行的研究和进步不断增强化疗方案，其在非何杰金氏淋巴瘤治疗中的流行和重要性仍然至关重要。

受快速发展的医疗基础设施和不断上升的疾病盛行率的推动，亚太地区非何杰金氏淋巴瘤治疗产业将在 2032 年之前保持显着的复合年增长率。该地区不断扩大的先进治疗方法和不断增加的肿瘤学研究投资促进了这一增长。此外，诊断率的提高和大量患者群体进一步推动了市场扩张。亚太地区在医疗保健方面的进步以及对解决癌症护理需求的承诺使其成为非何杰金氏淋巴瘤治疗市场预测的主要贡献者。

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 日本
- 中国
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 沙乌地阿拉伯
- 南非
- 阿联酋
- 中东和非洲其他地区

第 9 章：公司简介

Astellas Pharma US, Inc.
AstraZeneca PLC
Bayer AG
Bristol Myers Squibb Company
Celgene Corporation
Eli Lilly and Company
GSK plc
F. Hoffmann La-Roche Ltd.
Janssen Pharmaceuticals Inc.
Seagen Inc
Takeda Pharmaceutical Company Ltd.
Teva Pharmaceutical Industries Ltd.

简介目录

Product Code: 9696

Global Non-Hodgkin Lymphoma Therapeutics Market will record a 7.4% CAGR during 2024 and 2032 due to advancements in drug development and the expansion of treatment options. Innovations in pharmaceuticals, such as targeted therapies and combination treatments, enhance the effectiveness of managing various lymphoma subtypes. These advancements address unmet medical needs and offer personalized treatment approaches. As new therapies are developed and approved, they provide more choices for patients and healthcare providers, contributing to increased market demand and a broader range of effective treatment options.

For instance, in April 2023, the FDA approved Polivy(R) (polatuzumab vedotin-piiq) combined with Rituxan(R) (rituximab) and other drugs, marking the first new B-cell lymphoma treatment in 20 years. This combo reduces disease progression risk by 27%. This new treatment offers a notable reduction in disease progression risk, enhancing therapeutic options for B-cell lymphoma patients. The introduction of such a novel therapy after 20 years underscores the market's potential for innovation and growth. It may drive increased interest and investment in the development of new therapies, influencing market dynamics and expanding treatment choices.

The non-Hodgkin lymphoma therapeutics market is classified based on type, therapy type, gender, and region.

The T-cell lymphomas segment will experience a noteworthy surge by 2032, attributed to the increasing recognition of T-cell lymphomas' complex and diverse subtypes. This segment's growth is driven by the demand for targeted therapies and advancements in understanding the specific mechanisms of T-cell lymphomas. Ongoing research and development efforts are leading to the creation of more effective and personalized treatments, addressing the unique challenges posed by T-cell lymphomas and enhancing patient outcomes, thus driving market expansion.

The chemotherapy segment will witness a substantial uptick between 2024 and 2032, propelled by its established role as a primary treatment method. Chemotherapy remains a cornerstone in managing non-Hodgkin lymphoma, effectively targeting and destroying cancer cells. Its wide range of available drugs and proven efficacy in various stages of the disease contribute to its dominant market position. As ongoing research and advancements continue to enhance chemotherapy regimens, its prevalence and importance in non-Hodgkin lymphoma treatment remain crucial.

Asia Pacific non-Hodgkin lymphoma therapeutics industry will uphold a notable CAGR through 2032, spurred by its rapidly growing healthcare infrastructure and increasing disease prevalence. The region's expanding access to advanced treatments and rising investments in oncology research contribute to this growth. In addition, improving diagnosis rates and a significant patient population further drive market expansion. Asia Pacific's advancements in healthcare and commitment to addressing cancer care needs position it as a primary contributor to the non-Hodgkin lymphoma therapeutics market forecasts.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360°synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing incidence of Non-Hodgkin lymphoma
  - 3.2.1.2 Expanding investment and R&D activities
  - 3.2.1.3 Approval of new drugs and therapies
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of treatment
  - 3.2.2.2 Stringent regulatory requirements
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 B-cell lymphomas
- 5.2.1 Diffuse large B-cell lymphoma (DLBCL)
- 5.2.2 Follicular lymphoma
- 5.2.3 Mantle cell lymphoma
- 5.2.4 Other B-cell lymphomas
5.3 T-cell lymphoma
- 5.3.1 Peripheral T-cell lymphoma
- 5.3.2 Cutaneous T-cell lymphoma
- 5.3.3 Anaplastic large cell lymphoma
- 5.3.4 Other T-cell lymphomas

Chapter 6 Market Estimates and Forecast, By Therapy Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Chemotherapy
6.3 Targeted therapy
6.4 Radiation therapy
6.5 Other therapy types

Chapter 7 Market Estimates and Forecast, By Gender, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Male
7.3 Female

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa